此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing

2015年5月12日 更新者:Exact Sciences Corporation
The objective of this study is to confirm the sensitivity and specificity of a stool DNA test for detection of colorectal cancer and pre-cancer.

研究概览

详细说明

Patients who have recently undergone a colonoscopy that resulted with normal findings will be asked to submit a stool sample (s) (at least 30 days AFTER colonoscopy).

研究类型

观察性的

注册 (实际的)

674

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Tucson、Arizona、美国、85710
        • Desert Sun Clinical Research
    • California
      • Pomona、California、美国、91767
        • REMEK Research
      • San Diego、California、美国、92101
        • Sharp Rees-Stealy
      • Santa Monica、California、美国、90404
        • Southern California Medical Gastroenterology Group, Inc
    • Florida
      • Miami、Florida、美国、33173
        • Miami Research Associates
    • Georgia
      • Marietta、Georgia、美国、30067
        • Atlanta Gastroenterology Associates
    • Illinois
      • Rockford、Illinois、美国、61107
        • Rockford Gastroenterology Associates, Ltd.
    • Louisiana
      • Metairie、Louisiana、美国、70006
        • New Orleans Research Institue
    • Maryland
      • Columbia、Maryland、美国、21045
        • Columbia Medical Practice
    • Pennsylvania
      • Perkasie、Pennsylvania、美国、18944
        • Main Line Gastroenterology
    • Texas
      • Austin、Texas、美国、78705
        • Professional Quality Research, Inc.
    • Utah
      • Ogden、Utah、美国、84405
        • Advanced Research Institute
      • Sandy、Utah、美国、84094
        • Advanced Research Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 84年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients are at average risk of developing colorectal cancer at the time of their colonoscopy and the colonoscopy resulted in normal findings.

描述

Inclusion Criteria:

  • Subject is male or female, 50-84 years of age, inclusive.
  • Subject is at average risk for development of CRC and has undergone a screening colonoscopy with a normal result at least 30 days and no more than 120 days before providing a stool sample for the study. For the purposes of this study, a "normal" colonoscopy result is defined as no polyps of any size detected or removed (including benign, hyperplastic polyps).
  • Subject is able to understand the study procedures, and is able to provide signed consent to participate in the study and authorizes release of relevant protected health information through signing a HIPAA consent.
  • Subject is able and willing to provide stool samples at least 30 days and no more than 120 days after undergoing a colonoscopy that resulted in normal findings, according to the written instructions provided to them.

Exclusion Criteria:

  • Subject has any condition which, in the opinion of the investigator should preclude participation in the study.
  • Subject had any findings on recent or any previous colonoscopy including benign, and/or hyperplastic polyps of any size. (Note: Tissue biopsies that result in no histopathology findings are acceptable.)
  • Subject has a history or recent diagnosis of CRC or adenoma.
  • Subject has a history of aerodigestive tract cancer.
  • Subject has had a positive fecal occult blood test or FIT within the previous six (6) months.
  • Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease.
  • Subject has had overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)
  • Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:

    • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
    • Greater than or equal to (>=)2 first-degree relatives who have been diagnosed with colon cancer. (Note: first-degree relatives include parents, siblings and offspring).
    • One first-degree relative with CRC diagnosed before the age of 60.
    • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP).
    • Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome").
    • Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:仅案例

队列和干预

团体/队列
Average risk patients
Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Sensitivity and Specificity of the Exact CRC diagnostic screening test.
大体时间:10 months
The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.
10 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Graham Lidgard, PhD、Chief Scientific officer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年10月1日

初级完成 (实际的)

2012年8月1日

研究完成 (实际的)

2012年9月1日

研究注册日期

首次提交

2012年5月11日

首先提交符合 QC 标准的

2012年5月14日

首次发布 (估计)

2012年5月17日

研究记录更新

最后更新发布 (估计)

2015年5月13日

上次提交的符合 QC 标准的更新

2015年5月12日

最后验证

2015年5月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅